- Iron supplements
- Erythropoietin or erythrocyte-stimulating agents
- Vitamin B12 supplements
- Folic acid supplements
Anemia In Chronic Kidney Disease Market was valued at USD 873.2 million in 2023 and is anticipated to grow at a CAGR of 5.8% over 2024-2030. Anemia in chronic kidney disease is a common complication of CKD, particularly in the later stages. CKD affects the kidneys' ability to produce erythropoietin, a hormone that stimulates the production of red blood cells. As a result, individuals with CKD may experience a decrease in red blood cell production, leading to anemia. The Anemia in chronic kidney disease market refers to the pharmaceutical and medical products and services aimed at managing anemia in CKD patients.
Treatment options typically include iron supplementation, erythropoiesis-stimulating agents (ESAs), and blood transfusions. ESAs are synthetic versions of erythropoietin and are commonly used to stimulate the production of red blood cells in CKD patients. Iron supplements may also be prescribed, as iron deficiency can exacerbate anemia in CKD. The market for anemia in CKD treatment is significant due to the prevalence of CKD and the impact of anemia on patients' quality of life and overall health. The prevalence of chronic kidney disease can vary significantly in different regions globally. For instance, according to the Centers for Disease Control and Prevention, CKD is common among US adults, around more than 1 in 7 and 4% of US adults are estimated to have chronic kidney disease in 2021. Moreover, Pharmaceutical companies develop and market drugs targeting anemia in CKD patients, and medical devices for blood testing and monitoring are also part of the market. For instance, Akebia Therapeutics launched Auryxia (Ferric Citrate) for the treatment of chronic kidney disease.
Anemia In Chronic Kidney Disease Market Key Developments:
- In October 2020, the Division of Nephrology, Department of Internal Medicine, Kaohsiung Medical University Chung-Ho memorial hospital Kaohsiung, Taiwan under the sponsorship of Panion & BF Biotech Inc. doing a study on PBF-1681 (Ferric Citrate) for the treatment of iron deficiency anemia in patients with chronic kidney diseases.
Anemia In Chronic Kidney Disease Market Summary
Study Period
2024-2030
Base Year
2023
CAGR
5.8%
Largest Market
North America
Fastest Growing Market
Asia Pacific
Anemia In Chronic Kidney Disease Market Dynamics
Anemia in Chronic Kidney Disease (CKD) is a significant market driven by several key factors. The growing prevalence of CKD globally is a major growth driver, as anemia often accompanies advanced CKD stages. Rising awareness among healthcare professionals and patients regarding the importance of early detection and management of anemia further propels the market growth. The development of innovative erythropoiesis-stimulating agents (ESAs) and iron therapies, along with ongoing research and clinical trials, presents opportunities for market expansion. Moreover, the increasing elderly population, who are more prone to CKD and anemia, contributes to the market's growth. Additionally, the demand for cost-effective and efficient anemia management solutions, especially in developing regions, creates a favorable environment for market players. Overall, the Anemia in Chronic Kidney Disease Market holds promising prospects due to these growth drivers and opportunities.
North-America Got Significant Share
Anemia In Chronic Kidney Disease Market Region Analysis
The anemia in chronic kidney disease (CKD) Market in the USA faces unique challenges and exhibits various growth factors. One of the significant challenges is the increasing prevalence of CKD and anemia in the aging population, as the USA has a large elderly demographic. Additionally, reimbursement issues for anemia management therapies and treatment costs may pose obstacles for patients and healthcare providers. Regulatory complexities and safety concerns surrounding erythropoiesis-stimulating agents (ESAs) have also affected market growth. However, there are several growth factors to consider. Advancements in medical technologies and increased awareness among healthcare professionals and patients contribute to early diagnosis and intervention for anemia in CKD patients.
According to the Centers for Disease Control and Prevention, about 35.5 million people in the US are estimated to have CKD in 2021. Moreover, ongoing research and clinical trials in the field of anemia management provide potential breakthroughs. The robust healthcare infrastructure and substantial investments in the pharmaceutical and biotechnology sectors stimulate the development of novel therapies for anemia in CKD. The USA's focus on value-based care and improving patient outcomes fuels the demand for effective anemia treatment options. Overall, the Anemia in Chronic Kidney Disease Market in the USA shows promising growth prospects, driven by these factors and challenges.
Latin America
Europe
Asia Pacific
Middle East
North America
Key Features of the Reports
- The anemia in chronic kidney disease market report provides granular level information about the market size, regional market share, historic market (2019-2023), and forecast (2024-2030)
- The report covers in-detail insights about the competitor’s overview, company share analysis, key market developments, and key strategies
- The report outlines drivers, restraints, unmet needs, and trends that are currently affecting the market
- The report tracks recent innovations, key developments, and start-up details that are actively working in the market
- The report provides a plethora of information about market entry strategies, regulatory framework, and reimbursement scenario
Anemia In Chronic Kidney Disease Market Segmentation
By Treatment
By Product Type
- Tablets
- Injectable
By Dosage Forms
- Solid
- Liquid
By Route of Administration
- Oral
- Parenteral
By Age
- Pediatrics
- Adults
- Geriatrics
By End User
- Hospital pharmacy
- Online Pharmacy
- Retail pharmacy
Frequently Asked Questions
The Anemia in chronic kidney disease market was valued at USD 873.2 million in 2022 and is expected to grow at 5.8% CAGR over the forecast period 2023 – 2029.
Key opportunities for the anemia in chronic kidney disease market include Technological advancements and an increase in approval of drugs for the treatment of renal anemia, improved healthcare facilities, and government initiatives in spreading awareness about the symptoms and the available treatment for renal anemia, also increase in healthcare investment day by day will witness lucrative growth opportunities in the forecast period.
Key trends in the Anemia in Chronic Kidney Disease market include the development of novel erythropoiesis-stimulating agents (ESAs), increasing focus on personalized medicine approaches, and the adoption of telemedicine for remote patient monitoring and care.
Vifor Pharma, Sandoz International GmbH, Contract Pharmacal Corp., Akebia Therapeutics Inc., Amgen Inc., Rockwell Medical Inc., Covis Pharma GmbH, and Hoffmann-La Roche Ltd. are prominent companies operating in the field of Anemia In Chronic Kidney Disease market.
| 1.Executive Summary |
| 2.Global Anemia In Chronic Kidney Disease Market Introduction |
| 2.1.Global Anemia In Chronic Kidney Disease Market - Taxonomy |
| 2.2.Global Anemia In Chronic Kidney Disease Market - Definitions |
| 2.2.1.Treatment |
| 2.2.2.Product Type |
| 2.2.3.Dosage Forms |
| 2.2.4.Route of Administration |
| 2.2.5.Region |
| 3.Global Anemia In Chronic Kidney Disease Market Dynamics |
| 3.1. Drivers |
| 3.2. Restraints |
| 3.3. Opportunities/Unmet Needs of the Market |
| 3.4. Trends |
| 3.5. Product Landscape |
| 3.6. New Product Launches |
| 3.7. Impact of COVID 19 on Market |
| 4.Global Anemia In Chronic Kidney Disease Market Analysis, 2019 - 2023 and Forecast 2024 - 2030 |
| 4.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million) |
| 4.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) |
| 4.3. Market Opportunity Analysis |
| 5.Global Anemia In Chronic Kidney Disease Market By Treatment, 2019 - 2023 and Forecast 2024 - 2030 (Sales Value USD Million) |
| 5.1. Iron supplements |
| 5.1.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million) |
| 5.1.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 5.1.3. Market Opportunity Analysis |
| 5.2. Erythropoietin or erythrocyte-stimulating agents |
| 5.2.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million) |
| 5.2.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 5.2.3. Market Opportunity Analysis |
| 5.3. Vitamin B12 supplements |
| 5.3.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million) |
| 5.3.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 5.3.3. Market Opportunity Analysis |
| 5.4. Folic acid supplements |
| 5.4.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million) |
| 5.4.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 5.4.3. Market Opportunity Analysis |
| 6.Global Anemia In Chronic Kidney Disease Market By Product Type, 2019 - 2023 and Forecast 2024 - 2030 (Sales Value USD Million) |
| 6.1. Tablets |
| 6.1.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million) |
| 6.1.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 6.1.3. Market Opportunity Analysis |
| 6.2. Injectable |
| 6.2.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million) |
| 6.2.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 6.2.3. Market Opportunity Analysis |
| 7.Global Anemia In Chronic Kidney Disease Market By Dosage Forms, 2019 - 2023 and Forecast 2024 - 2030 (Sales Value USD Million) |
| 7.1. Solid |
| 7.1.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million) |
| 7.1.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 7.1.3. Market Opportunity Analysis |
| 7.2. Liquid |
| 7.2.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million) |
| 7.2.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 7.2.3. Market Opportunity Analysis |
| 8.Global Anemia In Chronic Kidney Disease Market By Route of Administration, 2019 - 2023 and Forecast 2024 - 2030 (Sales Value USD Million) |
| 8.1. Oral |
| 8.1.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million) |
| 8.1.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 8.1.3. Market Opportunity Analysis |
| 8.2. Parenteral |
| 8.2.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million) |
| 8.2.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 8.2.3. Market Opportunity Analysis |
| 9.Global Anemia In Chronic Kidney Disease Market By Region, 2019 - 2023 and Forecast 2024 - 2030 (Sales Value USD Million) |
| 9.1. North America |
| 9.1.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million) |
| 9.1.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 9.1.3. Market Opportunity Analysis |
| 9.2. Europe |
| 9.2.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million) |
| 9.2.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 9.2.3. Market Opportunity Analysis |
| 9.3. Asia Pacific (APAC) |
| 9.3.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million) |
| 9.3.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 9.3.3. Market Opportunity Analysis |
| 9.4. Middle East and Africa (MEA) |
| 9.4.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million) |
| 9.4.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 9.4.3. Market Opportunity Analysis |
| 9.5. Latin America |
| 9.5.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million) |
| 9.5.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 9.5.3. Market Opportunity Analysis |
| 10.North America Anemia In Chronic Kidney Disease Market ,2019 - 2023 and Forecast 2024 - 2030 (Sales Value USD Million) |
| 10.1. Treatment Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 10.1.1.Iron supplements |
| 10.1.2.Erythropoietin or erythrocyte-stimulating agents |
| 10.1.3.Vitamin B12 supplements |
| 10.1.4.Folic acid supplements |
| 10.2. Product Type Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 10.2.1.Tablets |
| 10.2.2. Injectable |
| 10.3. Dosage Forms Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 10.3.1.Solid |
| 10.3.2.Liquid |
| 10.4. Route of Administration Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 10.4.1.Oral |
| 10.4.2.Parenteral |
| 10.5. Country Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 10.5.1.United States of America (USA) |
| 10.5.2.Canada |
| 11.Europe Anemia In Chronic Kidney Disease Market ,2019 - 2023 and Forecast 2024 - 2030 (Sales Value USD Million) |
| 11.1. Treatment Analysis and Forecast by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 11.1.1.Iron supplements |
| 11.1.2.Erythropoietin or erythrocyte-stimulating agents |
| 11.1.3.Vitamin B12 supplements |
| 11.1.4.Folic acid supplements |
| 11.2. Product Type Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 11.2.1.Tablets |
| 11.2.2. Injectable |
| 11.3. Dosage Forms Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 11.3.1.Solid |
| 11.3.2.Liquid |
| 11.4. Route of Administration Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 11.4.1.Oral |
| 11.4.2.Parenteral |
| 11.5. Country Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 11.5.1.Germany |
| 11.5.2.France |
| 11.5.3.Italy |
| 11.5.4.United Kingdom (UK) |
| 11.5.5.Spain |
| 12.Asia Pacific (APAC) Anemia In Chronic Kidney Disease Market ,2019 - 2023 and Forecast 2024 - 2030 (Sales Value USD Million) |
| 12.1. Treatment Analysis and Forecast by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 12.1.1.Iron supplements |
| 12.1.2.Erythropoietin or erythrocyte-stimulating agents |
| 12.1.3.Vitamin B12 supplements |
| 12.1.4.Folic acid supplements |
| 12.2. Product Type Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 12.2.1.Tablets |
| 12.2.2. Injectable |
| 12.3. Dosage Forms Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 12.3.1.Solid |
| 12.3.2.Liquid |
| 12.4. Route of Administration Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 12.4.1.Oral |
| 12.4.2.Parenteral |
| 12.5. Country Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 12.5.1.China |
| 12.5.2.India |
| 12.5.3.Australia and New Zealand (ANZ) |
| 12.5.4.Japan |
| 12.5.5.Rest of APAC |
| 13.Middle East and Africa (MEA) Anemia In Chronic Kidney Disease Market ,2019 - 2023 and Forecast 2024 - 2030 (Sales Value USD Million) |
| 13.1. Treatment Analysis and Forecast by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 13.1.1.Iron supplements |
| 13.1.2.Erythropoietin or erythrocyte-stimulating agents |
| 13.1.3.Vitamin B12 supplements |
| 13.1.4.Folic acid supplements |
| 13.2. Product Type Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 13.2.1.Tablets |
| 13.2.2. Injectable |
| 13.3. Dosage Forms Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 13.3.1.Solid |
| 13.3.2.Liquid |
| 13.4. Route of Administration Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 13.4.1.Oral |
| 13.4.2.Parenteral |
| 13.5. Country Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 13.5.1.GCC Countries |
| 13.5.2.South Africa |
| 13.5.3.Rest of MEA |
| 14.Latin America Anemia In Chronic Kidney Disease Market ,2019 - 2023 and Forecast 2024 - 2030 (Sales Value USD Million) |
| 14.1. Treatment Analysis and Forecast by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 14.1.1.Iron supplements |
| 14.1.2.Erythropoietin or erythrocyte-stimulating agents |
| 14.1.3.Vitamin B12 supplements |
| 14.1.4.Folic acid supplements |
| 14.2. Product Type Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 14.2.1.Tablets |
| 14.2.2. Injectable |
| 14.3. Dosage Forms Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 14.3.1.Solid |
| 14.3.2.Liquid |
| 14.4. Route of Administration Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 14.4.1.Oral |
| 14.4.2.Parenteral |
| 14.5. Country Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 14.5.1.Brazil |
| 14.5.2.Mexico |
| 14.5.3.Rest of LA |
| 15. Competition Landscape |
| 15.1. Market Player Profiles (Introduction, Brand/Product Sales, Financial Analysis, Product Offerings, Key Developments, Collaborations, M & A, Strategies, and SWOT Analysis) |
| 15.2.1. Vifor Pharma |
| 15.2.2.Sandoz International GmbH |
| 15.2.3.Contract Pharmacal Corp. |
| 15.2.4.Akebia Therapeutics Inc. |
| 15.2.5.Amgen Inc. |
| 15.2.6.Rockwell Medical Inc. |
| 15.2.7.Covis Pharma GmbH |
| 15.2.8.Hoffmann-La Roche Ltd |
| 15.2.9.Pfizer Inc. |
| 15.2.10.Novartis AG |
| 15.2.11.Johnson & Johnson |
| 15.2.12.Teva Pharmaceutical Industries Ltd. |
| 16. Research Methodology |
| 17. Appendix and Abbreviations |
- Vifor Pharma
- Sandoz International GmbH
- Contract Pharmacal Corp.
- Akebia Therapeutics Inc.
- Amgen Inc.
- Rockwell Medical Inc.
- Covis Pharma GmbH
- Hoffmann-La Roche Ltd
- Pfizer Inc.
- Novartis AG
- Johnson & Johnson
- Teva Pharmaceutical Industries Ltd.